# Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)

> **NCT03331848** · PHASE2 · WITHDRAWN · sponsor: **Prexton Therapeutics**

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Placebo oral capsule
- **DRUG:** PXT002331 - 20mg

## Key facts

- **NCT ID:** NCT03331848
- **Lead sponsor:** Prexton Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-01-15
- **Primary completion:** 2019-02-01
- **Final completion:** 2019-02-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2018-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03331848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03331848, "Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03331848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*